vs

Side-by-side financial comparison of PAMT CORP (PAMT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $141.3M, roughly 1.1× PAMT CORP). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -20.7%, a 15.2% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -15.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-25.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -12.0%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

PAMT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.1× larger
TARS
$151.7M
$141.3M
PAMT
Growing faster (revenue YoY)
TARS
TARS
+143.5% gap
TARS
128.4%
-15.1%
PAMT
Higher net margin
TARS
TARS
15.2% more per $
TARS
-5.5%
-20.7%
PAMT
More free cash flow
TARS
TARS
$37.9M more FCF
TARS
$13.0M
$-25.0M
PAMT
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-12.0%
PAMT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PAMT
PAMT
TARS
TARS
Revenue
$141.3M
$151.7M
Net Profit
$-29.3M
$-8.4M
Gross Margin
Operating Margin
-27.0%
-5.3%
Net Margin
-20.7%
-5.5%
Revenue YoY
-15.1%
128.4%
Net Profit YoY
7.4%
63.8%
EPS (diluted)
$-1.38
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAMT
PAMT
TARS
TARS
Q4 25
$141.3M
$151.7M
Q3 25
$150.3M
$118.7M
Q2 25
$151.1M
$102.7M
Q1 25
$155.3M
$78.3M
Q4 24
$166.5M
$66.4M
Q3 24
$182.6M
$48.1M
Q2 24
$182.9M
$40.8M
Q1 24
$182.6M
$27.6M
Net Profit
PAMT
PAMT
TARS
TARS
Q4 25
$-29.3M
$-8.4M
Q3 25
$-5.6M
$-12.6M
Q2 25
$-9.6M
$-20.3M
Q1 25
$-8.1M
$-25.1M
Q4 24
$-31.6M
$-23.1M
Q3 24
$2.4M
$-23.4M
Q2 24
$-2.9M
$-33.3M
Q1 24
$281.0K
$-35.7M
Operating Margin
PAMT
PAMT
TARS
TARS
Q4 25
-27.0%
-5.3%
Q3 25
-3.8%
-12.2%
Q2 25
-7.3%
-21.6%
Q1 25
-5.9%
-33.5%
Q4 24
-22.6%
-36.8%
Q3 24
1.3%
-52.3%
Q2 24
-0.4%
-81.6%
Q1 24
-0.4%
-136.5%
Net Margin
PAMT
PAMT
TARS
TARS
Q4 25
-20.7%
-5.5%
Q3 25
-3.7%
-10.6%
Q2 25
-6.4%
-19.8%
Q1 25
-5.2%
-32.1%
Q4 24
-19.0%
-34.8%
Q3 24
1.3%
-48.7%
Q2 24
-1.6%
-81.6%
Q1 24
0.2%
-129.4%
EPS (diluted)
PAMT
PAMT
TARS
TARS
Q4 25
$-1.38
$-0.17
Q3 25
$-0.27
$-0.30
Q2 25
$-0.46
$-0.48
Q1 25
$-0.37
$-0.64
Q4 24
$-1.44
$-0.57
Q3 24
$0.11
$-0.61
Q2 24
$-0.13
$-0.88
Q1 24
$0.01
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAMT
PAMT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$83.7M
$417.3M
Total DebtLower is stronger
$333.9M
$72.4M
Stockholders' EquityBook value
$210.5M
$343.4M
Total Assets
$697.9M
$562.2M
Debt / EquityLower = less leverage
1.59×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAMT
PAMT
TARS
TARS
Q4 25
$83.7M
$417.3M
Q3 25
$115.6M
$401.8M
Q2 25
$117.3M
$381.1M
Q1 25
$102.7M
$407.9M
Q4 24
$110.7M
$291.4M
Q3 24
$92.3M
$317.0M
Q2 24
$114.0M
$323.6M
Q1 24
$125.8M
$298.5M
Total Debt
PAMT
PAMT
TARS
TARS
Q4 25
$333.9M
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$325.6M
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
PAMT
PAMT
TARS
TARS
Q4 25
$210.5M
$343.4M
Q3 25
$239.5M
$335.1M
Q2 25
$244.9M
$332.6M
Q1 25
$269.6M
$342.5M
Q4 24
$277.5M
$224.5M
Q3 24
$308.9M
$237.5M
Q2 24
$306.7M
$252.2M
Q1 24
$314.6M
$275.2M
Total Assets
PAMT
PAMT
TARS
TARS
Q4 25
$697.9M
$562.2M
Q3 25
$715.2M
$534.6M
Q2 25
$707.9M
$495.0M
Q1 25
$712.6M
$500.8M
Q4 24
$741.7M
$377.0M
Q3 24
$756.7M
$376.3M
Q2 24
$733.5M
$376.8M
Q1 24
$746.4M
$349.3M
Debt / Equity
PAMT
PAMT
TARS
TARS
Q4 25
1.59×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
1.17×
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAMT
PAMT
TARS
TARS
Operating Cash FlowLast quarter
$-5.8M
$19.3M
Free Cash FlowOCF − Capex
$-25.0M
$13.0M
FCF MarginFCF / Revenue
-17.7%
8.6%
Capex IntensityCapex / Revenue
13.6%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-23.4M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAMT
PAMT
TARS
TARS
Q4 25
$-5.8M
$19.3M
Q3 25
$5.9M
$18.3M
Q2 25
$12.2M
$-29.4M
Q1 25
$5.0M
$-20.7M
Q4 24
$15.2M
$-22.2M
Q3 24
$15.5M
$-8.7M
Q2 24
$18.7M
$-14.4M
Q1 24
$9.6M
$-37.8M
Free Cash Flow
PAMT
PAMT
TARS
TARS
Q4 25
$-25.0M
$13.0M
Q3 25
$2.5M
$16.3M
Q2 25
$5.9M
$-30.4M
Q1 25
$-6.8M
$-21.2M
Q4 24
$-39.9M
$-22.3M
Q3 24
$-33.6M
$-8.9M
Q2 24
$4.1M
$-15.4M
Q1 24
$-12.2M
$-38.0M
FCF Margin
PAMT
PAMT
TARS
TARS
Q4 25
-17.7%
8.6%
Q3 25
1.7%
13.8%
Q2 25
3.9%
-29.6%
Q1 25
-4.4%
-27.1%
Q4 24
-24.0%
-33.5%
Q3 24
-18.4%
-18.6%
Q2 24
2.2%
-37.8%
Q1 24
-6.7%
-137.5%
Capex Intensity
PAMT
PAMT
TARS
TARS
Q4 25
13.6%
4.2%
Q3 25
2.3%
1.6%
Q2 25
4.2%
1.0%
Q1 25
7.6%
0.8%
Q4 24
33.1%
0.1%
Q3 24
26.9%
0.6%
Q2 24
8.0%
2.5%
Q1 24
12.0%
0.6%
Cash Conversion
PAMT
PAMT
TARS
TARS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
6.44×
Q2 24
Q1 24
34.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PAMT
PAMT

Freight Transportation Service$123.1M87%
Fuel Surcharge$18.2M13%

TARS
TARS

Segment breakdown not available.

Related Comparisons